Zacks Small Cap Analysis – GRCE: Progress Report – Model Slux
By John Vandermosten, CFA NASDAQ:GRCE READ THE FULL GRCE RESEARCH REPORT Grace Therapeutics, Inc (NASDAQ:GRCE) will quickly submit its new drug software (NDA) to the FDA, which we anticipate within the subsequent few weeks. The corporate just lately held a pre-NDA assembly with the FDA and got here away feeling carefully aligned with the company … Read more
